Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Ligand Pharmaceuticals (LGND) Equity Average (2016 - 2025)

Historic Equity Average for Ligand Pharmaceuticals (LGND) over the last 15 years, with Q3 2025 value amounting to $889.4 million.

  • Ligand Pharmaceuticals' Equity Average rose 1004.25% to $889.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $889.4 million, marking a year-over-year increase of 1004.25%. This contributed to the annual value of $765.7 million for FY2024, which is 1794.16% up from last year.
  • Per Ligand Pharmaceuticals' latest filing, its Equity Average stood at $889.4 million for Q3 2025, which was up 1004.25% from $812.0 million recorded in Q2 2025.
  • In the past 5 years, Ligand Pharmaceuticals' Equity Average ranged from a high of $889.4 million in Q3 2025 and a low of $621.9 million during Q1 2023
  • Over the past 5 years, Ligand Pharmaceuticals' median Equity Average value was $797.8 million (recorded in 2022), while the average stood at $766.4 million.
  • As far as peak fluctuations go, Ligand Pharmaceuticals' Equity Average tumbled by 2295.34% in 2023, and later skyrocketed by 2212.2% in 2024.
  • Ligand Pharmaceuticals' Equity Average (Quarter) stood at $816.6 million in 2021, then decreased by 13.44% to $706.9 million in 2022, then fell by 3.18% to $684.4 million in 2023, then grew by 22.12% to $835.8 million in 2024, then increased by 6.41% to $889.4 million in 2025.
  • Its Equity Average stands at $889.4 million for Q3 2025, versus $812.0 million for Q2 2025 and $813.0 million for Q1 2025.